European Commission Approves Janssen’s TREMFYA (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today…
Zokinvy (lonafarnib) is the first approved Treatment for Hutchinson-Gilford Progeria Syndrome and Some Progeroid Laminopathies
The U.S. Food and Drug Administration has approved Zokinvy (lonafarnib)…
New indication expands use of Brilinta (ticagrelor) beyond cardiovascular disease to patients with mild-to-moderate stroke
AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the…
Rekambys (rilpivirine) and Vocabria injection (cabotegravir) First long-acting injectable antiretroviral therapy for HIV
EMA has recommended the granting of marketing authorisations for two new…
Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) first FDA approved treatment for Ebola virus
The U.S. Food and Drug Administration approved Inmazeb (atoltivimab,…
Opdivo (nivolumab) in combination with Yervoy (ipilimumab) newly approved first-line treatment of adults with malignant pleural mesothelioma.
The U.S. Food and Drug Administration has approved Opdivo (nivolumab) in…
Jyseleca (filgotinib), approved in the EU for the treatment of adults with moderate to severe rheumatoid arthritis
Jyseleca is a medicine for treating adults with moderate to severe rheumatoid…
Nucala (mepolizumab), First Drug to Treat Group of Rare Blood Disorders in Nearly 14 Years
The Food and Drug Administration has approved Nucala (mepolizumab) for adults…
Velphoro (sucroferric oxyhydroxide) has been approved for the treatment of children with chronic kidney disease
EMA has recommended granting an extension of indication for Velphoro…
New indication for Olumiant (baricitinib) as oral treatment for moderate to severe atopic dermatitis
EMA has recommended granting an extension of indication to Olumiant…